We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The vaccine has received a conditional marketing authorization in the EU and is now being administered to high-risk groups in the EU member states. Read More
Pfizer and BioNTech now anticipate manufacturing up to 2 billion doses of their highly effective COVID-19 vaccine by the end of the year as vaccination efforts ramp up and demand for shots increases around the globe. Read More
The European Union has secured 200 million more doses of the Pfizer/BioNTech COVID-19 vaccine, with an option to buy 100 million additional doses, bringing the total number of potential doses contracted for to 600 million. Read More
Dewpoint will receive an upfront payment and potential future milestone payments totaling $239 million, plus royalties from any approved products. Read More
OBT will receive an upfront payment and additional payments for reaching discovery, clinical and regulatory goals, as well as royalties on future sales. Read More
German vaccine developer CureVac has secured a deal with Bayer to help gain regulatory approvals worldwide for its messenger RNA-based COVID-19 vaccine candidate, CVnCoV. Read More
South Africa received the discounted price because it is considered a developing nation and because the vaccine is being evaluated in a phase 3 trial in the country. Read More